James I. Healy has served as a member of our board of directors since November 2014. Dr. Healy has been a General Partner at Sofinnova Ventures, a venture capital firm, since 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, a venture capital firm, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories), a research-based pharmaceutical company and ISTA Pharmaceuticals, Inc., a company specializing in ophthalmic pharmaceutical products. Dr. Healy is currently on the board of directors of Ascendis Pharma A/S, a clinical-stage biopharmaceutical company, Amarin Corporation plc, a commercial-stage biopharmaceutical company, Auris Medical Holding AG, a specialty pharmaceutical company focused on tinnitus, Coherus BioSciences, Inc., a biologics platform company, and several private companies. Previously, Dr. Healy served as a board member of Anthera Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammation and autoimmune diseases, from 2006 to 2014; Durata Therapeutics, Inc., a pharmaceutical company focused on infectious and acute diseases, from 2009 to 2013; InterMune, Inc., a biotechnology company focused on orphan fibrotic pulmonary disease, from 1999 to 2014; KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of monoclonal antibody therapeutics, from 2001 to 2014; Hyperion Therapeutics, Inc., a commercial-stage orphan disease company, from 2007 to 2015 and several private companies. Dr. Healy holds an M.D. and Ph.D. in Immunology from Stanford University School of Medicine and performed neuroscience research at the University of Virginia School of Medicine. Dr. Healy holds a Bachelors of Arts in Molecular Biology and Scandinavian Studies from the University of California at Berkeley.
What is James Healy's net worth?
The estimated net worth of James Healy is at least $1.46 million as of January 13th, 2023. Mr. Healy owns 32,500 shares of Natera stock worth more than $1,460,875 as of February 7th. This net worth estimate does not reflect any other assets that Mr. Healy may own. Learn More about James Healy's net worth.
How do I contact James Healy?
Has James Healy been buying or selling shares of Natera?
James Healy has not been actively trading shares of Natera over the course of the past ninety days. Most recently, on Thursday, July 22nd, James Healy bought 2,400 shares of Natera stock. The stock was acquired at an average cost of $113.00 per share, with a total value of $271,200.00. Following the completion of the transaction, the director now directly owns 32,472 shares of the company's stock, valued at $3,669,336. Learn More on James Healy's trading history.
Who are Natera's active insiders?
Natera's insider roster includes Roy Baynes (Director), Roelof Botha (Director), Michael Brophy (CFO), Rowan Chapman (Director), Steven Chapman (CEO), Todd Cozzens (Director), James Healy (Director), Gail Marcus (Director), Daniel Rabinowitz (Insider), Matthew Rabinowitz (Chairman), Herm Rosenman (Director), Robert Schueren (COO), and Jonathan Sheena (Insider). Learn More on Natera's active insiders.
Are insiders buying or selling shares of Natera?
During the last twelve months, Natera insiders bought shares 2 times. They purchased a total of 372,820 shares worth more than $11,323,786.80. During the last twelve months, insiders at the medical research company sold shares 62 times. They sold a total of 164,110 shares worth more than $6,807,068.72. The most recent insider tranaction occured on February, 1st when CFO Michael Burkes Brophy sold 19,326 shares worth more than $844,159.68. Insiders at Natera own 10.3% of the company.
Learn More about insider trades at Natera. Information on this page was last updated on 2/1/2023.
